The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about their dangers. “We are not there yet, and recursive self-improvement is not ...
Recursion Pharmaceuticals (RXRX) remains a 'Sell' as its ~$1.8B valuation is unsupported by clinical or commercial progress. REC-4881's efficacy in FAP is unremarkable versus Celebrex, with uncertain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results